Seelos Therapeutics Inc (SEEL): Vitaros U.S. NDA Re-Submission on Track...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	7
Posts	1044
Boards Moderated	0
Alias Born	06/26/2013

mecosmo2

Re: None

Wednesday, 07/12/2017 8:34:59 PM

Wednesday, July 12, 2017 8:34:59 PM

Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that the Vitaros drug-device combination human factor testing study required by the Food and Drug Administration (FDA) is underway.

"In November of 2016, the FDA designated Vitaros as a drug-device combination and required Apricus to provide additional information regarding the proper use of the applicator in the planned NDA re-submission," stated Richard W. Pascoe, Chief Executive Officer. "We have since confirmed the necessary regulatory requirements for a drug-device combination product and have initiated the required human factors study which we believe is in accordance with the FDA guidance. We expect this study will be completed in the second quarter of this year and the results will be incorporated into our planned Vitaros NDA re-submission, which remains on track for the third quarter of this year."

About Apricus Biosciences, Inc.